Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability.

Leukotrienes (LT) are a group of proinflammatory lipid mediators that are implicated in the pathogenesis and progression of atherosclerosis. Here we report that mRNA levels for the three key proteins in LTB4 biosynthesis, namely 5-lipoxygenase (5-LO), 5-LO-activating protein (FLAP), and LTA4 hydrolase (LTA4H), are significantly increased in human atherosclerotic plaque (n = 72) as compared with healthy controls (n = 6). Neither LTC4 synthase nor any of the LT receptors exhibits significantly increased mRNA levels. Immunohistochemical staining revealed abundant expression of 5-LO, FLAP, and LTA4H protein, colocalizing in macrophages of intimal lesions. Human lesion tissue converts arachidonic acid into significant amounts of LTB4, and a selective, tight-binding LTA4H inhibitor can block this activity. Furthermore, expression of 5-LO and LTA4H, but not FLAP, is increased in patients with recent or ongoing symptoms of plaque instability, and medication with warfarin correlates with increased levels of FLAP mRNA. In contrast to human plaques, levels of 5-LO mRNA are not significantly increased in plaque tissues from two atherosclerosis-prone mouse strains, and mouse plaques exhibit segregated cellular expression of LTA4H and 5-LO as well as strong increases of CysLT1 and CysLT2 mRNA. These discrepancies indicate that phenotypic changes in the synthesis and action of LT in specific mouse models of atherosclerosis should be cautiously translated into human pathology. The abundant expression of LTA4H and correlation with plaque instability identify LTA4H as a potential target for pharmacological intervention in treatment of human atherosclerosis.

[1]  Takao Shimizu,et al.  A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis , 1997, Nature.

[2]  T. Cohnert,et al.  Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Jilly F. Evans,et al.  The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm , 2004, Nature Medicine.

[4]  J. Haeggström.  Leukotriene A4 Hydrolase/Aminopeptidase, the Gatekeeper of Chemotactic Leukotriene B4 Biosynthesis* , 2004, Journal of Biological Chemistry.

[5]  C. Funk.  Leukotriene modifiers as potential therapeutics for cardiovascular disease , 2005, Nature Reviews Drug Discovery.

[6]  A. Lusis,et al.  Identification of 5-Lipoxygenase as a Major Gene Contributing to Atherosclerosis Susceptibility in Mice , 2002, Circulation research.

[7]  Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. , 2004 .

[8]  G. Hansson,et al.  Electrocardiographic characterization of stress-induced myocardial infarction in atherosclerotic mice. , 2005, Acta physiologica Scandinavica.

[9]  I. Ollmann,et al.  PROBING THE ACTIVITIES AND MECHANISMS OF LEUKOTRIENE A4 HYDROLASE WITH SYNTHETIC INHIBITORS , 1998 .

[10]  Takao Shimizu,et al.  A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. , 2000, The Journal of experimental medicine.

[11]  R. de Caterina,et al.  Leukotriene B4 production in human atherosclerotic plaques. , 1988, Biomedica biochimica acta.

[12]  G. Hansson,et al.  Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Suttles,et al.  Role of Leukotriene B4 Receptors in the Development of Atherosclerosis: Potential Mechanisms , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[14]  H. Showell,et al.  Leukotriene B4 Receptor Antagonism Reduces Monocytic Foam Cells in Mice , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[15]  Jilly F. Evans,et al.  Characterization of the human cysteinyl leukotriene CysLT1 receptor , 1999, Nature.

[16]  Jesse D. Roberts,et al.  Inhibition of Atherogenesis in BLT1-Deficient Mice Reveals a Role for LTB4 and BLT1 in Smooth Muscle Cell Recruitment , 2005, Circulation.

[17]  F. Cipollone,et al.  Association Between 5-Lipoxygenase Expression and Plaque Instability in Humans , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[18]  K. Austen,et al.  Leukotriene C4 synthase: a pivotal enzyme in cellular biosynthesis of the cysteinyl leukotrienes. , 2002, Prostaglandins & other lipid mediators.

[19]  John Savill,et al.  Resolution of inflammation: the beginning programs the end , 2005, Nature Immunology.

[20]  T. Hla.  Prostaglandins & other lipid mediators: a new phase, a new team. , 2004, Prostaglandins & other lipid mediators.

[21]  Vilmundur Gudnason,et al.  A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction , 2006, Nature Genetics.

[22]  B. Samuelsson.  Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. , 1983, Science.

[23]  Jilly F. Evans,et al.  Characterization of the Human Cysteinyl Leukotriene 2 Receptor* , 2000, The Journal of Biological Chemistry.

[24]  G. Hansson.  Inflammation, atherosclerosis, and coronary artery disease. , 2005, The New England journal of medicine.

[25]  J. Gulcher,et al.  The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke , 2004, Nature Genetics.

[26]  Aloke V. Finn,et al.  Atherosclerotic Plaque Progression and Vulnerability to Rupture: Angiogenesis as a Source of Intraplaque Hemorrhage , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[27]  D. Steinberg,et al.  Gene expression in macrophage-rich human atherosclerotic lesions. 15-lipoxygenase and acetyl low density lipoprotein receptor messenger RNA colocalize with oxidation specific lipid-protein adducts. , 1991, The Journal of clinical investigation.